[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588672":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":58,"collaborators":32,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":32,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":32,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":32,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A1","EXPERIMENTAL","Dose escalation will be conducted using accelerated titration and traditional 3+3 design. Dose Escalation Level includes 12 levels, QW IV. Dose extension will be carried out at the selected level.",[13],"Drug: SSS59",{"label":15,"type":10,"description":16,"interventionNames":17},"Part A2","Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level includes 12 levels, Q2W IV. Dose extension will be carried out at the selected level.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Part A3","Dose extension will be carried out at the selected dose level, Q3W, IV.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Part B","Indication extension will be carried out at the selected level.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","SSS59","A humanized antibody targeting MUC17",[9,15,19,23],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Qi Li, MD","CONTACT","86+13818207333","Leeqi2001@hotmail.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":32,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Shanghai First People's Hospital","RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":48,"coordinates":49},"Point",[50,51],121.45806,31.22222,{"lat":51,"lon":50},[54],{"name":55,"role":36,"phone":56,"phoneExt":32,"email":57},"Wenqian Geng","86+021-36126254","shiyilunli@sina.com",{"type":59,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100588672","phase-1-a-phase-i-clinical-study-of-sss59-monotherapy-in-patients-with-advanced-malignant-tumors-100588672",false,"NCT06944444","A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors","A Phase I Clinical Study of the Safety, Pharmacokinetics, and Antitumor Activity of SSS59 in Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Histologically and\u002For cytologically documented local advanced or recurrent or metastatic malignancies.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival \\>3 months.\n* Signed informed consent form.\n* Must have adequate organ function.\n\nExclusion Criteria:\n\n* Any remaining AEs \\> grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss and fatigue.\n* Pregnant or nursing women or women\u002Fmen who are ready to give birth.\n* symptomatic central nervous system metastasis.\n* Allergy to other antibody drugs or any excipients in the study drugs.\n* Underwent major surgery within 4 weeks prior to first dosing.\n* The patient is participating in another clinical study, unless it is an observational (non-intervention) clinical study or a follow-up period of an intervention study.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":71,"type":72},154,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.",[78],"Malignant Tumors","2025-04-27",{"date":81,"type":82},"2025-04-29","ACTUAL",{"date":79,"type":82},{"date":85,"type":72},"2027-12-31",{"name":5,"class":6},1]